Solventum’s Q2 2026 Earnings: What to Expect

Barchart
在Barchart上打开
Solventum’s Q2 2026 Earnings: What to Expect

Maplewood, Minnesota-headquartered Solventum Corporation (SOLV) is a global healthcare company that develops medical technologies, products, and software to improve patient outcomes and streamline healthcare delivery. It currently has a market cap of $13.7 billion.

The healthcare company is expected to announce its Q2 2026 earnings on Wednesday, Aug. 5, after the market closes. Ahead of the event, analysts expect SOLV to report a profit of $1.91 per share on a diluted basis, up 13% from $1.69 per share in the year-ago quarter. The company beat the consensus estimates in each of the past four quarters, which is noteworthy.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

For the current year, analysts expect SOLV to report EPS of $6.58, up 7.7% from $6.11 in fiscal 2025

www.barchart.com

Over the past 52 weeks, SOLV has lagged behind the S&P 500 Index’s ($SPX19.1% gains, and the State Street Health Care Select Sector SPDR Fund’s (XLV22.2% returns, with shares up 8.7% during this period.

www.barchart.com

Solventum has lagged the broader market over the past year amid investor concerns about its weak growth outlook and profitability. The company has reported little to no organic revenue growth, while analysts expect flat sales over the next 12 months, signaling subdued demand. Additionally, its free cash flow margins have deteriorated significantly over the past years, raising concerns about higher capital requirements and the company's ability to improve profitability following its spin-off from 3M.

Analysts’ consensus opinion on SOLV is reasonably bullish, with a “Moderate Buy” rating overall. Out of 16 analysts covering the stock, seven advise a “Strong Buy” rating, seven give a “Hold,” and two recommend a “Strong Sell.” SOLV’s average analyst price target is $83.67, indicating a potential upside of 6.5% from the current levels. 


On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Nasdaq Futures Slip as Chip Rally Falters Ahead of Alphabet Earnings This High-Yield Bank Stock Just Raised Its Dividend by 11% Barclays Just Upgraded CarMax Stock. Here's Why. GameStop Just Raised Its Stake in eBay to 10% After the Board Rejected Its Takeover Bid. Ryan Cohen Is Preparing for a Bigger Fight.